{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T11:36:07Z","timestamp":1768563367259,"version":"3.49.0"},"reference-count":44,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T00:00:00Z","timestamp":1741651200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100018448","name":"Gert und Susanna Mayer Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100018448","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["por-journal.com"],"crossmark-restriction":true},"short-container-title":["Pathol. Oncol. Res."],"abstract":"<jats:p>Sarcomas with an EWSR1::POU2AF3(COLCA2) fusion are a very recently described entity of preferentially sinonasal origin and with undifferentiated round\/spindle cell morphology. We established a novel cell line (PF1095) carrying a EWSR1::POU2AF3 fusion from the malignant pleural effusion of a 25-year-old sarcoma patient. The patient was first diagnosed with poorly differentiated neuroendocrine carcinoma based on tumor cell morphology and positivity to markers such as EMA, synaptophysin, and CD56. Later, the EWSR1 translocation was identified in the tumor cells with unknown partners and the patient received chemotherapy according to the Ewing 2008 protocol in combination with surgery and proton beam radiotherapy. At the time of cell line establishment, the disease progressed to pleural sarcomatosis with pleural effusion. In the cell line, we identified POU2AF3 as a fusion partner of EWSR1 and a TP53 frameshift deletion. Next, we determined the sensitivity of PF1095 cells to the currently approved chemotherapies in comparison to two conventional Ewing sarcoma lines (EW-7 and MHH-ES1) with the two most frequent EWSR::FLI1 fusions. Finally, we tested potential new combination therapies. We performed cell viability, proliferation, and cell cycle assays. We found that the proliferation rate of PF1095 cells was much slower than the EWSR1::FLI1 fusion lines and they also had a lower sensitivity to both irinotecan and doxorubicin treatment. Expression level of SLFN11, a predictor of sensitivity to DNA damaging agents, was also lower in PF1095 cells. Combination treatment with the PARP inhibitors olaparib and irinotecan or doxorubicin synergistically reduced cell viability and induced cell death and cell cycle arrest. This unique cell model provides an opportunity to test therapeutic approaches preclinically for this novel and aggressive sarcoma entity.<\/jats:p>","DOI":"10.3389\/pore.2025.1611986","type":"journal-article","created":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:11:37Z","timestamp":1741666297000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Characterization of a novel sarcoma cell line with an EWSR1::POU2AF3 fusion"],"prefix":"10.3389","volume":"31","author":[{"given":"Hannah","family":"Schwab","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maximilian","family":"Kerkhoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline","family":"Plaumann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"Collaud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uta","family":"Dirksen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dirk","family":"Theegarten","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Herold","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stavros","family":"Kalbourtzis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Balazs","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luca","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,11]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1038\/s41572-022-00393-3","article-title":"Small round cell sarcomas","volume":"8","author":"Cidre-Aranaz","year":"2022","journal-title":"Nat Rev Dis Primers"},{"key":"B2","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1053\/j.semdp.2021.10.002","article-title":"From the ashes of \u201cEwing-like\u201d sarcoma: a contemporary update of the classification, immunohistochemistry, and molecular genetics of round cell sarcomas","volume":"39","author":"Kallen","year":"2022","journal-title":"Semin Diagn Pathol"},{"key":"B3","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1038\/s41572-018-0003-x","article-title":"Ewing sarcoma","volume":"4","author":"Gr\u00fcnewald","year":"2018","journal-title":"Nat Rev Dis Primers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1007\/s00428-019-02720-8","article-title":"Ewing sarcoma and Ewing-like tumors","volume":"476","author":"Sbaraglia","year":"2020","journal-title":"Virchows Arch"},{"key":"B5","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1016\/j.cancergen.2011.07.008","article-title":"Promiscuous partnerships in Ewing's sarcoma","volume":"204","author":"Sankar","year":"2011","journal-title":"Cancer Genet"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.15761\/CRR.1000111","article-title":"The histogenesis of ewing sarcoma","volume":"1","author":"Tu","year":"2017","journal-title":"Cancer Rep Rev"},{"key":"B7","doi-asserted-by":"publisher","first-page":"16176","DOI":"10.3390\/ijms160716176","article-title":"Sequencing overview of ewing sarcoma: a journey across genomic, epigenomic and transcriptomic landscapes","volume":"16","author":"Sand","year":"2015","journal-title":"Int J Mol Sci"},{"key":"B8","doi-asserted-by":"publisher","first-page":"111761","DOI":"10.1016\/j.celrep.2022.111761","article-title":"Systematic multi-omics cell line profiling uncovers principles of Ewing sarcoma fusion oncogene-mediated gene regulation","volume":"41","author":"Orth","year":"2022","journal-title":"Cell Rep"},{"key":"B9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1007\/s00428-017-2080-8","article-title":"Undifferentiated \u201cround\u201d cell (\u201cEwing-like\u201d) sarcoma: not always so-round nor Ewing-like","volume":"470","author":"Wang","year":"2017","journal-title":"Virchows Arch"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/bjc.2012.57","article-title":"The ganglioside antigen G(D2) is surface-expressed in Ewing sarcoma and allows for MHC-independent immune targeting","volume":"106","author":"Kailayangiri","year":"2012","journal-title":"Br J Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"1685","DOI":"10.3390\/jcm10081685","article-title":"Ewing sarcoma-diagnosis, treatment, clinical challenges and future perspectives","volume":"10","author":"Zollner","year":"2021","journal-title":"J Clin Med"},{"key":"B12","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1158\/2159-8290.CD-14-0622","article-title":"Genomic landscape of Ewing sarcoma defines an aggressive subtype with co-association of STAG2 and TP53 mutations","volume":"4","author":"Tirode","year":"2014","journal-title":"Cancer Discov"},{"key":"B13","doi-asserted-by":"publisher","first-page":"359","DOI":"10.1007\/BF03256302","article-title":"Diagnostic and prognostic sarcoma signatures","volume":"12","author":"Davicioni","year":"2008","journal-title":"Mol Diagn Ther"},{"key":"B14","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/pin.13293","article-title":"Ewing and Ewing-like sarcomas: a morphological guide through genetically-defined entities","volume":"73","author":"Yoshida","year":"2023","journal-title":"Pathol Int"},{"key":"B15","doi-asserted-by":"publisher","first-page":"70","DOI":"10.32074\/1591-951X-213","article-title":"The 2020 WHO classification of soft tissue tumours: news and perspectives","volume":"113","author":"Sbaraglia","year":"2021","journal-title":"Pathologica"},{"key":"B16","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1002\/gcc.23136","article-title":"POU2AF3-rearranged sarcomas: a novel tumor defined by fusions of EWSR1 or FUS to a gene formerly designated COLCA2","volume":"62","author":"Hiemenz","year":"2023","journal-title":"Genes Chromosomes Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"2330","DOI":"10.1002\/ijc.28557","article-title":"Identification of genes expressed by immune cells of the colon that are regulated by colorectal cancer-associated variants","volume":"134","author":"Peltekova","year":"2014","journal-title":"Int J Cancer"},{"key":"B18","doi-asserted-by":"publisher","first-page":"4557","DOI":"10.1038\/s41598-021-84042-x","article-title":"rs1944919 on chromosome 11q23.1 and its effector genes COLCA1\/COLCA2 confer susceptibility to primary biliary cholangitis","volume":"11","author":"Hitomi","year":"2021","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1038\/s41586-022-04842-7","article-title":"OCA-T1 and OCA-T2 are coactivators of POU2F3 in the tuft cell lineage","volume":"607","author":"Wu","year":"2022","journal-title":"Nature"},{"key":"B20","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1002\/gcc.20171","article-title":"EWSR1 is fused to POU5F1 in a bone tumor with translocation t(6;22)(p21;q12)","volume":"43","author":"Yamaguchi","year":"2005","journal-title":"Genes Chromosomes Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"100337","DOI":"10.1016\/j.modpat.2023.100337","article-title":"EWSR1::POU2AF3(COLCA2) sarcoma: an aggressive, polyphenotypic sarcoma with a head and neck predilection","volume":"36","author":"Koshyk","year":"2023","journal-title":"Mod Pathol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1097\/PAS.0000000000002000","article-title":"Recurrent EWSR1::COLCA2 fusions define a novel sarcoma with spindle\/round cell morphology and strong predilection for the sinonasal tract","volume":"47","author":"Agaimy","year":"2023","journal-title":"Am J Surg Pathol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/j.celrep.2014.09.028","article-title":"Targeting the DNA repair pathway in Ewing sarcoma","volume":"9","author":"Stewart","year":"2014","journal-title":"Cell Rep"},{"key":"B24","doi-asserted-by":"publisher","first-page":"100404","DOI":"10.1016\/j.jbo.2021.100404","article-title":"One oncogene, several vulnerabilities: EWS\/FLI targeted therapies for Ewing sarcoma","volume":"31","author":"Flores","year":"2021","journal-title":"J Bone Oncol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"7999","DOI":"10.1002\/jcp.27558","article-title":"Ewing-like sarcoma: an emerging family of round cell sarcomas","volume":"234","author":"Renzi","year":"2019","journal-title":"J Cell Physiol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1007\/s11547-018-0877-4","article-title":"Soft tissue sarcomas: new opportunity of treatment with PARP inhibitors?","volume":"124","author":"Mangoni","year":"2019","journal-title":"Radiol Med"},{"key":"B27","doi-asserted-by":"publisher","first-page":"1608","DOI":"10.1158\/0008-5472.CAN-11-3648","article-title":"PARP-1 inhibition as a targeted strategy to treat Ewing's sarcoma","volume":"72","author":"Brenner","year":"2012","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4184","DOI":"10.1158\/1078-0432.CCR-14-2112","article-title":"SLFN11 is a transcriptional target of EWS-FLI1 and a determinant of drug response in ewing sarcoma","volume":"21","author":"Tang","year":"2015","journal-title":"Clin Cancer Res"},{"key":"B30","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.1158\/1535-7163.MCT-21-0089","article-title":"SLFN11 is widely expressed in pediatric sarcoma and induces variable sensitization to replicative stress caused by DNA-damaging agents","volume":"20","author":"Gartrell","year":"2021","journal-title":"Mol Cancer Ther"},{"key":"B31","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1186\/1471-2407-14-813","article-title":"Phase II study of olaparib in patients with refractory Ewing sarcoma following failure of standard chemotherapy","volume":"14","author":"Choy","year":"2014","journal-title":"BMC Cancer"},{"key":"B32","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1002\/pbc.24767","article-title":"A phase II window study of irinotecan (CPT-11) in high risk Ewing sarcoma: a Euro-E.W.I.N.G. study","volume":"61","author":"Morland","year":"2014","journal-title":"Pediatr Blood Cancer"},{"key":"B33","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.ejca.2020.06.014","article-title":"A phase I trial of talazoparib and irinotecan with and without temozolomide in children and young adults with recurrent or refractory solid malignancies","volume":"137","author":"Federico","year":"2020","journal-title":"Eur J Cancer"},{"key":"B34","first-page":"3273","article-title":"Establishment and characterization of a new Ewing's sarcoma cell line from a malignant pleural effusion","volume":"27","author":"Schiavo","year":"2007","journal-title":"Anticancer Res"},{"key":"B35","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","article-title":"TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy","volume":"178","author":"Hegedus","year":"2023","journal-title":"Lung Cancer"},{"key":"B36","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1158\/0008-5472.CAN-09-1947","article-title":"Drug combination studies and their synergy quantification using the Chou-Talalay method","volume":"70","author":"Chou","year":"2010","journal-title":"Cancer Res"},{"key":"B37","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1002\/ijc.31601","article-title":"Germline mutations in 40 cancer susceptibility genes among Chinese patients with high hereditary risk breast cancer","volume":"144","author":"Li","year":"2019","journal-title":"Int J Cancer"},{"key":"B38","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.3389\/fonc.2020.01000","article-title":"Disialoganglioside GD2 expression in solid tumors and role as a target for cancer therapy","volume":"10","author":"Nazha","year":"2020","journal-title":"Front Oncol"},{"key":"B39","doi-asserted-by":"publisher","first-page":"358","DOI":"10.3390\/biom12030358","article-title":"Anti-GD2 directed immunotherapy for high-risk and metastatic neuroblastoma","volume":"12","author":"Chan","year":"2022","journal-title":"Biomolecules"},{"key":"B40","doi-asserted-by":"publisher","first-page":"272","DOI":"10.3390\/cancers15010272","article-title":"Current state of immunotherapy and mechanisms of immune evasion in ewing sarcoma and osteosarcoma","volume":"15","author":"Evdokimova","year":"2022","journal-title":"Cancers (Basel)"},{"key":"B41","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1056\/NEJMoa2303383","article-title":"Atezolizumab for advanced alveolar soft Part Sarcoma","volume":"389","author":"Chen","year":"2023","journal-title":"N Engl J Med"},{"key":"B42","doi-asserted-by":"publisher","first-page":"404810","DOI":"10.1155\/2012\/404810","article-title":"MAPK\/ERK signaling in osteosarcomas, ewing sarcomas and chondrosarcomas: therapeutic implications and future directions","volume":"2012","author":"Chandhanayingyong","year":"2012","journal-title":"Sarcoma"},{"key":"B43","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s13402-023-00867-w","article-title":"Host-derived growth factors drive ERK phosphorylation and MCL1 expression to promote osteosarcoma cell survival during metastatic lung colonization","volume":"47","author":"McAloney","year":"2024","journal-title":"Cell Oncol (Dordr)"},{"key":"B44","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.ccell.2017.01.006","article-title":"Chemosensitive relapse in small cell lung cancer proceeds through an EZH2-SLFN11 Axis","volume":"31","author":"Gardner","year":"2017","journal-title":"Cancer Cell"}],"container-title":["Pathology and Oncology Research"],"original-title":[],"link":[{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1611986\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,11]],"date-time":"2025-03-11T04:11:43Z","timestamp":1741666303000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.por-journal.com\/articles\/10.3389\/pore.2025.1611986\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,11]]},"references-count":44,"alternative-id":["10.3389\/pore.2025.1611986"],"URL":"https:\/\/doi.org\/10.3389\/pore.2025.1611986","relation":{},"ISSN":["1532-2807"],"issn-type":[{"value":"1532-2807","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,11]]},"article-number":"1611986"}}